Cell therapy using genetically modified T cells, known as CAR-T, is showing solid results in treating blood cancers that fail to respond to standard treatments. Data published in the scientific journal Blood Advances indicates that among patients with refractory diffuse large B-cell lymphoma, the three-year overall survival rate rose from 10% to 59% after CAR-T therapy, while progression-free survival increased from 6% to 48%. Before this technology, median survival in these cases stood at roughly six months, with complete remission rates of just 7%.

Researcher Martín Hernán Bonamino, head of the Cellular and Gene Therapy Program at Brazil's National Cancer Institute (INCA), highlighted in The Conversation and reported by Folha de S.Paulo that the technique re-engineers patient immune cells to target tumor antigens. However, commercial imported versions costing over R$ 2 million (about $350,000) per patient remain out of reach for most Brazilians and place a severe strain on healthcare budgets.

To enable distribution through Brazil's public healthcare system, the SUS (Sistema Único de Saúde), domestic academic centers are creating proprietary production methods. Projects led by INCA, the University of São Paulo (USP), the University of Brasília (UnB), and the Albert Einstein Israeli Hospital aim to manufacture vectors and cell lines locally, sharply cutting costs and national dependence on foreign supply chains.

While clinical trial data is encouraging, broad rollout across public hospitals requires further regulatory clearance. The Brazilian versions remain in regulated clinical trial phases with health agency Anvisa, meaning the treatment is not yet universally accessible across routine oncology wards.

Patients and families facing refractory lymphomas or leukemias should consult their treating hematologists. Oncologists can assess whether a patient qualifies for ongoing approved clinical trials in Brazil or recommend verified standard care protocols within the SUS network while national manufacturing expands.